Foreword |
|
vii | |
|
Contributors |
|
xv | |
|
Part I Basic Foundations of Normal and Abnormal Cardiac Electrical Activity |
|
|
|
|
|
The Past and Promise of Basic Cardiac Electrophysiology |
|
|
3 | (8) |
|
|
Basic Physiology of Ion Channel Function |
|
|
11 | (13) |
|
|
|
Developmental Aspects of the Electrophysiology of the Heart: Function Follows Form |
|
|
24 | (13) |
|
|
|
|
Anatomic and Histopathological Characteristics of the Conductive Tissues of the Heart |
|
|
37 | (15) |
|
|
|
|
Neural Regulation of the Heart in Health and Disease |
|
|
52 | (13) |
|
|
Mechanisms of Cardiac Arrhythmia |
|
|
65 | (68) |
|
|
|
|
Mechanisms of Action of Antiarrhythmic Drugs |
|
|
133 | (12) |
|
|
|
Mechanoelectrical Interactions and Their Role in Electrical Function of the Heart |
|
|
145 | (16) |
|
|
|
The Role of Cellular Sodium and Calcium Loading in Cardiac Energetics and Arrhythmogeneis: Contribution of the Late Sodium Current |
|
|
161 | (9) |
|
|
|
|
Sodium Ion Channelopathies |
|
|
170 | (17) |
|
|
|
|
L-Type Calcium Channel Disease |
|
|
187 | (7) |
|
|
|
|
|
K+ Channelopathies (IKs and IKr) |
|
|
194 | (13) |
|
|
|
Channelopathies of Cardiac Inwardly Rectifying Potassium Channels |
|
|
207 | (11) |
|
|
|
|
|
|
|
|
Calcium Release Channels (Ryanodine Receptors) and Arrhythmogenesis |
|
|
218 | (14) |
|
|
|
Caveolae and Arrhythmogenesis |
|
|
232 | (15) |
|
|
Senescence and Arrhythmogenesis |
|
|
247 | (14) |
|
|
|
|
Comparisons of Substrates Responsible for Atrial Versus Ventricular Fibrillation |
|
|
261 | (20) |
|
|
|
|
Single Nucleotide Polymorphisms in Health and Cardiac Disease |
|
|
281 | (9) |
|
|
Electrophysiological Remodeling in Dilated Cardiomyopathy and Heart Failure |
|
|
290 | (15) |
|
|
|
Ventricular Electrical Remodeling in Compensated Cardiac Hypertrophy |
|
|
305 | (11) |
|
|
|
Physiological and Other Biological Pacemakers |
|
|
316 | (15) |
|
|
|
|
|
Part II Clinical Rhythmology: Diagnostic Methods and Tools |
|
|
|
|
|
|
|
|
Diagnostic Electrocardiography |
|
|
331 | (13) |
|
|
Ambulatory Monitoring (Holter, Event Recorders, External, and Implantable Loop Recorders and Wireless Technology) |
|
|
344 | (9) |
|
|
|
|
|
|
|
Signal Averaged Electrocardiogram |
|
|
353 | (12) |
|
|
|
|
|
Heart Rate Variability: Measurements and Risk Stratification |
|
|
365 | (14) |
|
|
|
Surface Mapping and Magnetoelectrocardiography |
|
|
379 | (15) |
|
|
Microvolt T Wave Alternans: Mechanisms and Implications for Prediction of Sudden Cardiac Death |
|
|
394 | (15) |
|
|
|
|
|
Invasive Electrophysiologic Testing: Role in Sudden Death Prediction |
|
|
409 | (15) |
|
|
|
Provocative Testing in Inherited Arrhythmias |
|
|
424 | (10) |
|
|
|
Novel Predictors of Sudden Cardiac Death |
|
|
434 | (10) |
|
|
|
444 | (18) |
|
|
|
Part III Heritable Cardiac Channelopathies, Primary Electrical Diseases, and Clinical Syndromes |
|
|
|
|
|
|
|
|
Celebrating the Challenge of Cardiac Arrhythmias |
|
|
461 | (1) |
|
|
Congenital Long QT Syndrome |
|
|
462 | (21) |
|
|
|
|
|
Brugada Syndrome: Clinical and Genetic Aspects |
|
|
483 | (17) |
|
|
|
|
Brugada Syndrome: Cellular Mechanisms and Approaches to Therapy |
|
|
500 | (36) |
|
|
|
Catecholaminergic Polymorphic Ventricular Tachycardia |
|
|
536 | (9) |
|
|
|
|
Andersen-Tawil and Timothy Syndromes |
|
|
545 | (9) |
|
|
|
|
554 | (10) |
|
|
|
Progressive Cardiac Conduction Disease |
|
|
564 | (13) |
|
|
|
|
Familial Atrial Fibrillation and Standstill |
|
|
577 | (11) |
|
|
|
|
|
Idiopathic Ventricular Fibrillation |
|
|
588 | (22) |
|
|
|
Part IV Secondary Hereditary Electrical Diseases and Clinical Syndromes |
|
|
|
|
|
|
|
607 | (3) |
|
|
Arrhythmogenic Malignancies in Hypertrophic Cardiomyopathy |
|
|
610 | (17) |
|
|
|
|
|
Sudden Death in Dilated Cardiomyopathy and Skeletal Myopathies |
|
|
627 | (16) |
|
|
|
Ventricular Arrhythmias in Right Ventricular Dysplasia/Cardiomyopathy |
|
|
643 | (11) |
|
|
|
The Wolff-Parkinson-White Syndrome and the Risk of Sudden Death |
|
|
654 | (23) |
|
|
|
|
|
|
Part V Iatrongenic (Drug-Induced) Cardiac Channelopathies and Sudden Cardiac Death |
|
|
|
|
|
|
Drug-Induced Enhanced Risk for Sudden Cardiac Death in Clinical Practice, Clinical Research, and Drug Development |
|
|
673 | (4) |
|
|
Pharmacogenomics in Drug Development and Clinical Research |
|
|
677 | (14) |
|
|
Mechanisms of Drug-Induced Cardiac Toxicity |
|
|
691 | (14) |
|
|
Acquired (Drug-Induced) Long QT Syndrome |
|
|
705 | (14) |
|
|
|
|
Acquired Form of Brugada Syndrome |
|
|
719 | (14) |
|
|
Part VI Treatment Modalities |
|
|
|
|
|
|
|
731 | (2) |
|
|
Clinical Role of Antiarrhythmic Drugs in the Prevention of Sudden Death |
|
|
733 | (27) |
|
|
Nonantiarrhythmic Drugs in Sudden Death Prevention |
|
|
760 | (12) |
|
|
|
The Implantable Cardioverter Defibrillator: Technical and Clinical Considerations |
|
|
772 | (9) |
|
|
|
Beyond Sudden Death Prevention: Minimizing Implantable Cardioverter Defibrillator Shocks and Morbidity and Optimizing Efficacy |
|
|
781 | (20) |
|
|
|
|
|
Pacing and Cardiac Resynchronization |
|
|
801 | (8) |
|
|
Device Therapy for Remote Patient Management |
|
|
809 | (17) |
|
|
|
|
Catheter Ablation of Ventricular Tachycardia and Fibrillation |
|
|
826 | (13) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Surgical Treatment of Atrial Fibrillation |
|
|
839 | (14) |
|
|
Part VII Risk Stratification and Prevention of Sudden Cardiac Death in Acquired Clinical Conditions |
|
|
|
|
|
|
|
|
Screening for Risk of Sudden Cardiac Death |
|
|
851 | (2) |
|
|
Clinical Trials in Sudden Cardiac Death Prevention: Principles and Endpoints |
|
|
853 | (5) |
|
|
Risk Stratification for Sudden Death in Patients with Coronary Artery Disease |
|
|
858 | (15) |
|
|
|
Heart Failure and Sudden Death |
|
|
873 | (15) |
|
|
|
Neurological Conditions and Sudden Death |
|
|
888 | (10) |
|
|
|
Obstructive Sleep Apnea and Sudden Death |
|
|
898 | (13) |
|
|
|
Sudden Cardiac Death in Athletes |
|
|
911 | (13) |
|
|
|
|
|
|
Sudden Cardiac Death in Infancy: Focus on Prolonged Repolarization |
|
|
924 | (10) |
|
|
|
|
|
Sudden Cardiac Death in Kidney Diseases |
|
|
934 | (9) |
|
|
|
Index |
|
943 | |